BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 11502841)

  • 1. nm23-H1 immunoreactivity as a prognostic factor in differentiated thyroid carcinoma.
    Zafon C; Obiols G; Castellví J; Tallada N; Galofré P; Gemar E; Mesa J; Simó R
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3975-80. PubMed ID: 11502841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathological study on the expression of cell adhesion molecules and metastasis suppressor gene in thyroid follicular carcinoma and papillary carcinoma].
    Liu Y; Jiang C; Tan Y
    Zhonghua Bing Li Xue Za Zhi; 2002 Aug; 31(4):322-6. PubMed ID: 12417089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preferential reduction of nm23-H1 gene product in metastatic tissues from papillary and follicular carcinomas of the thyroid.
    Arai T; Yamashita T; Urano T; Masunaga A; Itoyama S; Itoh K; Shiku H; Sugawara I
    Mod Pathol; 1995 Apr; 8(3):252-6. PubMed ID: 7617649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of patients with insular carcinoma of the thyroid: the insular histotype is an independent predictor of poor prognosis.
    Pellegriti G; Giuffrida D; Scollo C; Vigneri R; Regalbuto C; Squatrito S; Belfiore A
    Cancer; 2002 Nov; 95(10):2076-85. PubMed ID: 12412160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. nm23-H1 protein immunoreactivity in laryngeal carcinoma.
    Lee CS; Redshaw A; Boag G
    Cancer; 1996 Jun; 77(11):2246-50. PubMed ID: 8635091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NM23-H1 immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas.
    Cheah PY; Cao X; Eu KW; Seow-Choen F
    Br J Cancer; 1998 Apr; 77(7):1164-8. PubMed ID: 9569056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.
    Heimann R; Lan F; McBride R; Hellman S
    Cancer Res; 2000 Jan; 60(2):298-304. PubMed ID: 10667580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
    Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
    Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
    Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of nm23-H1 predicts lymph node involvement in colorectal carcinoma.
    Tannapfel A; Köckerling F; Katalinic A; Wittekind C
    Dis Colon Rectum; 1995 Jun; 38(6):651-4. PubMed ID: 7774480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis of expression of nm23-H1/nucleoside diphosphate kinase in human thyroid carcinomas: lack of correlation between its expression and lymph node metastasis.
    Luo W; Matsuo K; Nagayama Y; Urano T; Furukawa K; Takeshita A; Nakayama T; Yokoyama N; Yamashita S; Izumi M
    Thyroid; 1993; 3(2):105-9. PubMed ID: 8396479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of nm23-H1 in stage I non-small cell lung cancer: a useful marker in prediction of metastases.
    Lai WW; Wu MH; Yan JJ; Chen FF
    Ann Thorac Surg; 1996 Nov; 62(5):1500-4. PubMed ID: 8893591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nm23 protein expression in thyroid neoplasms.
    Royds JA; Silcocks PB; Rees RC; Stephenson TJ
    Pathologica; 1994 Jun; 86(3):240-3. PubMed ID: 7808792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoreactivity of nm23-H1 protein in renal cell carcinoma.
    Kuo JY; Chang KM; Chen KK; Chang LS
    Anticancer Res; 1998; 18(1B):531-6. PubMed ID: 9568173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. nm23--relationship to the metastatic potential of breast carcinoma cell lines, primary human xenografts, and lymph node negative breast carcinoma patients.
    Russell RL; Geisinger KR; Mehta RR; White WL; Shelton B; Kute TE
    Cancer; 1997 Mar; 79(6):1158-65. PubMed ID: 9070493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. nm23-H1 protein immunoreactivity in cancers of the gallbladder, extrahepatic bile ducts and ampulla of Vater.
    Lee CS; Pirdas-Zivcic A
    Pathology; 1994 Oct; 26(4):448-52. PubMed ID: 7892048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of CD44V6 and nm23-H1 in thyroid papillary adenocarcinoma and lymph node metastasis].
    Wei Q; Fan S
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(1):5-7, 30. PubMed ID: 10681781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implication of nm23-H1 expression in colorectal carcinomas.
    Dursun A; Akyürek N; Günel N; Yamaç D
    Pathology; 2002 Oct; 34(5):427-32. PubMed ID: 12408341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of nm23 protein expression in renal cell carcinomas.
    Nakagawa Y; Tsumatani K; Kurumatani N; Cho M; Kitahori Y; Konishi N; Ozono S; Okajima E; Hirao Y; Hiasa Y
    Oncology; 1998; 55(4):370-6. PubMed ID: 9663430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.